IL17A and psoriasis vulgaris: Secukinumab (SECU) is a fully human anti-IL-17 monoclonal antibody approved for treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis for its ability to selectively neutralize IL-17A.